Political Quotes

On the recordMay 30, 2012
I would just like to remind my colleagues that from the Leadership Conference on Civil and Human Rights, we have this warning: We oppose this bill because it does not in any way adjust discrimination on the basis of sex or race. Rather, it is a veiled attempt to restrict health care for women of color under the guise of civil rights. This is the Leadership Conference on Civil and Human Rights. This bill tramples the rights of women under the guise of nondiscrimination while doing absolutely nothing to provide women with needed resources for their babies, female and male, so they can come into this world healthy and so both the mother and the child can thrive. This measure before us does absolutely nothing to empower women to make important life choices free from any family or community pressures they now face either to have an abortion, or to carry the pregnancy to term. In fact, it fails to employ the tested solutions that will reduce the pressures brought to bear on women to have sons. Experience around the world has shown that supporting women, providing them with tools to become independent and to be safe from violence, rather than criminal prohibitions, helps them resist the pressures of son preference.…
Said by
John Conyers
Democratic · Michigan
Source
govinfo.gov
May 30, 2012

Share

More from John Conyers

Sep 27, 2017

The title is Serious Risks Presented by the Anti-Regulatory Agenda of the 115th Congress and the Trump administration.

congress.gov
Oct 25, 2017

My amendment would exempt from H.R. 469 settlement agreements and consent decrees intended to prevent discrimination based on race, religion, national origin, or other protected category. Given the often systemic nature of discriminatory…

govinfo.gov
Oct 25, 2017

Although H.R. 469 has many flaws, I am particularly concerned that the bill's broad and ill-defined requirements would effectively delay and possibly deter civil enforcement agencies from providing general relief in discrimination cases…

govinfo.gov
Jul 26, 2017

We should of course remain vigilant about pay-for-delay schemes, whereby branded drug manufacturers pay generic manufacturers to delay the entry of a version of branded drugs as the patent on the branded drug expires.

congress.gov

Other voices in this conversation